Recruiting

Observational Study

Sponsor:

University of British Columbia

Code:

NCT07653347

Conditions

Respiratory Synctial Virus

Asthma Childhood

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Accepted

Study Details

Brief summary:

Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (<4 months) versus late (>6-9 months) in infancy.

Conditions

Respiratory Synctial Virus

Asthma Childhood

Study ID

NCT07653347

Start date

Jan 15, 2026

Status verified date

Jun, 2026

Completion date

Dec 1, 2029

Anticipated

Primary completion date

Jun 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Accepted

Inclusion Criteria:

Birthing parent/child pairs with a delivery date in April, May or June or September, October or November who delivered or are planning to deliver at BC Women's Hospital + Health Centre or a nearby, local hospital.

Exclusion Criteria:

Severe pregnancy-related complications or chronic medical conditions in the children making them automatically eligible to receiving RSV immunoprophylaxis in British Columbia (e.g. infants born prematurely < 35 weeks of gestation, or with chronic medical conditions).

Study Design

Enrollment

300 participants

Anticipated

Interventions and Outcome Measures

Arms

Fall group/cohort

Infants exposed to RSV <4 months of age (born September-November)

Spring group/cohort

Infants exposed to RSV >6-9 months of age (born April-June)

Primary outcome measure

  • RSV antibody response [ Time Frame: Post-respiratory season 2027 (May 2027) ]
  • Asthma symptoms [ Time Frame: at age 3 years old ]

Central Contacts and Locations

Central contacts

Pascal Lavoie, MDCM PhD FRCPC

604-875-2135plavoie@bcchr.ca

Allison Watts, PhD

604-875-2000awatts@bcchr.ca

Locations

BC Women's Hospital and Health Centre

Recruiting

Vancouver, British Columbia, Canada, V6H 3N1

Contacts

Pascal Lavoie, MD PhD

(604) 875-2000plavoie@bcchr.ca

Allison Watts, PhD

604-875-2135awatts@bcchr.ca

Principal Investigator:

Pascal Lavoie, MD PhD

More Information

Sponsor

University of British Columbia

Last update posted

Jun 17, 2026

Last verified

Jun, 2026

Keywords

  • cohort study
  • Immune response
  • infants
  • season of birth

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of British Columbia on 2026-06-17.